Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: April 23, 2025
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated April 23, 2025. The document serves to update the registration statements on Form F-3 and Form S-8. The provided text contains only the cover page, incorporation by reference statement, exhibit index, and signature block; it does not include the full text of the press release or financial statements.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It only indicates that a press release was issued on April 23, 2025, which is incorporated by reference, but the content of that release is not included in the input text.
Guidance, Outlook, and Risks
Management Commentary: The filing explicitly excludes a quotation from Jonathan Dickinson, Chairman of the Executive Board and CEO, from the incorporation by reference into the registration statements.
Guidance and Risks: No specific guidance, outlook, risk factors, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Exhibit 99.1 Content: Verify the full text of the press release dated April 23, 2025, to understand the specific news or event triggering this filing.
- Financial Impact: Review the company's most recent Form 20-F or quarterly reports for actual financial metrics, as this 6-K does not contain them.
- CEO Statement: Note that the CEO's specific quotation was excluded from the registration statement incorporation; investors should seek the original press release for his full comments.